We are confident that 2020 and 2021 will be very relevant years for regenerative medicine in Japan
In Conversation
Improving health financing resilience will be critical for achieving universal healthcare, particularly if countries are hit by second or third waves of COVID-19
The big picture trends of ageing populations and rising affluence, which lead to greater demand for specialty care products, are universal and, if anything, are moving…
All of our previous learnings and experiences around partnerships, engagement and community outreach from our efforts in HIV, HBV, and HCV have become critical as we…
We were the first Korean biotech to have independently developed, commercialized, marketed and exported an innovative drug
From my experience, many great ideas actually come from people unconstrained by the conventions and cultural uniformities of large organisations
Our cancer registers go back 50-60 years and represent excellent resources to draw on for researchers who are developing the next generation of efficacious cancer treatments
Despite the fact that I joined the company during the peak of the COVID-19 epidemic in China, we have achieved a number of milestones in the…
We have learned that to perform well in the US, we need to have a consistently robust pipeline instead of relying on just one or two…
Health is the largest focus area for public R&D in Norway even though we do not have a strong industrial tradition in this field
What we see clearly with COVID is the need for better technology and approaches to respiratory disease
Implementing a new organisational focus in line with the transformation plan would be a major challenge for any new GM but doing so remotely and without…
